You are here: Industry Insights > Lilly

News List

Lilly acquires biotech firm Protomer Technologies for $1bn pharmaceutical-technology
July 15, 2021
Eli Lilly has acquired a private biotech firm Protomer Technologies for a potential deal value of more than $1bn, including development and commercial milestones in the future.
Lilly and Verge Genomics partner to use AI for drug development pharmaceutical-technology
July 12, 2021
Eli Lilly has entered a three-year partnership with biotech company Verge Genomics to research and create new drugs for the treatment of amyotrophic lateral sclerosis (ALS), a motor neuron disease.
Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF pharmatimes
July 07, 2021
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of its SGLT2 inhibitor Jardiance in patients with heart failure with preserved ejection fraction (HFpEF).
Lilly's SURPASS-2 Results Published in The New England Journal of Medicine Show Tirzepatide Achieved Superior A1C and Body Weight Reductions Compared to Injectable Semaglutide in Adults with Type 2 di drugs
July 01, 2021
Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE: LLY) SURPASS-2 clinical trial.
Bajaj Healthcare applies to Indian patent office for compulsory licence for Baricitinib expresspharma
June 30, 2021
Considering Bajaj Healthcare's manufacturing capabilities and strong in-house R&D team, we can produce Baricitinib at very competitive and affordable prices in India, said Anil Jain, Joint MD, Bajaj Healthcare.
Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial pharmatimes
June 29, 2021
Eli Lilly has announced that its investigational GIP and GLP-1 inhibitor tirzepatide showed superiority over Novo Nordisk’s Ozempic in a Phase III trial.
Lilly's Donanemab receives U.S. FDA's Breakthrough Therapy Designation for Treatment of Alzheimer's disease drugs
June 29, 2021
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD).
European Commission approves Jardiance to treat heart failure expresspharma
June 22, 2021
The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and ...
Lilly plans head-to-head migraine study comparing Emgality with Nurtec ODT pharmatimes
June 18, 2021
Eli Lilly is planning to conduct a head-to-head study comparing its calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) Emgality with Biohaven Pharmaceuticals’ Nurtec for the preventative treatment of migraine.
NICE backs Lilly’s Taltz for axial spondyloarthritis pharmatimes
June 18, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Taltz for the treatment of active ankylosing spondylitis (axSpA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page